NEW YORK, NY / ACCESSWIRE / January 27, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SI Shareholders Click Here: https://www.zlk.com/pslra-1/silvergate-capital-loss-submission-form?prid=36019&wire=1
SUNL Shareholders Click Here: https://www.zlk.com/pslra-1/sunlight-financial-lawsuit-submission-form?prid=36019&wire=1
YMAB Shareholders Click Here: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=36019&wire=1

* ADDITIONAL INFORMATION BELOW *

Silvergate Capital Corporation (NYSE:SI)

SI Lawsuit on behalf of: investors who purchased November 11, 2020 - January 5, 2023
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/silvergate-capital-loss-submission-form?prid=36019&wire=1

According to the filed complaint, during the class period, Silvergate Capital Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's platform lacked sufficient controls and procedures to detect instances of money laundering; (2) Silvergate's customers had engaged in money laundering in amounts exceeding $425 million; (3) as a result of the foregoing, the Company was reasonably likely to receive regulatory scrutiny and face damages, including penalties and reputational harm; and (4) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Sunlight Financial Holdings Inc. f/k/a Spartan Acquisition Corp. II (NYSE:SUNL)

SUNL Lawsuit on behalf of: investors who purchased January 25, 2021 - September 28, 2022
Lead Plaintiff Deadline : February 14, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sunlight-financial-lawsuit-submission-form?prid=36019&wire=1

According to the filed complaint, during the class period, Sunlight Financial Holdings Inc. f/k/a Spartan Acquisition Corp. II made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective underwriting and risk evaluation with respect to its contractor advance program; (2) Sunlight lacked the oversight and periodic monitoring systems necessary to timely detect bad debt associated with its contractor advance program; (3) the Company lacked effective internal controls over accounting and reporting of non-cash advance receivables; (4) as a result, the Company would be forced to take a non-cash advance receivables impairment charge exceeding $30 million; and (5) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
Lead Plaintiff Deadline : March 20, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=36019&wire=1

According to the filed complaint, (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ('FDA') willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP